Market closed
Revolution Medicines/$RVMD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Ticker
$RVMD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
490
Website
RVMD Metrics
BasicAdvanced
$10B
Market cap
-
P/E ratio
-$3.56
EPS
1.40
Beta
-
Dividend rate
Price and volume
Market cap
$10B
Beta
1.4
52-week high
$60.59
52-week low
$19.05
Average daily volume
1.4M
Financial strength
Current ratio
14.244
Quick ratio
13.977
Long term debt to equity
5
Total debt to equity
5.536
Interest coverage (TTM)
-2,071.61%
Management effectiveness
Return on assets (TTM)
-28.56%
Return on equity (TTM)
-47.18%
Valuation
Price to revenue (TTM)
12,759.14
Price to book
6.35
Price to tangible book (TTM)
6.66
Price to free cash flow (TTM)
-17.177
Growth
Revenue change (TTM)
-97.16%
Earnings per share change (TTM)
7.43%
3-year revenue growth (CAGR)
-70.42%
3-year earnings per share growth (CAGR)
14.38%
What the Analysts think about RVMD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
RVMD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RVMD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RVMD News
AllArticlesVideos
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
GlobeNewsWire·1 week ago
Revolution Medicines to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $10B as of November 14, 2024.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of November 14, 2024.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of November 14, 2024.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.